Top Markets
Coin of the day
Defence Therapeutics Inc. Defence Therapeutics Inc.

Defence Therapeutics Inc.

DTC
Rank in Stocks #28133
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a... Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Share Price
$0.37430781
Last synced: 2026-08-19
Market Cap
$28.37M
Change (1 day)
2.00%
Change (1 year)
-13.46%
Country
CA
Trade Defence Therapeutics Inc. (DTC)

Category

P/S ratio for Defence Therapeutics Inc. (DTC)
P/S ratio as of 2026 TTM: 0
According to Defence Therapeutics Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Defence Therapeutics Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
11.28 -
US
10.13 -
NL
2.95 -
AU
- -
CH